Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors

Future Oncology

Volumn 11, Issue 8, 2015, Pages 1259-1274

  Santarpia, Mariacarmela ^a   Altavilla, Giuseppe ^a   Pitini, Vincenzo ^a   Rosell, Rafael ^b,c,d  

^a UNIVERSITY OF MESSINA   (Italy)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Germans Trias i Pujol Research Institute   (Spain)

^d Molecular Oncology Research (MORe) Foundation   (Spain)

Author keywords

adjuvant therapy; EGF receptor inhibitors; EGFR mutations; non small cell lung cancer; NSCLC; personalized treatment

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; DRUG EFFICACY; EARLY CANCER; GENE MUTATION; GENOTYPE; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CETUXIMAB; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84926472185     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.320     Document Type: Review

References (75)

1. Goldstraw P1, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007).
2. Hadziahmetovic M1, Loo BW, Timmerman RD et al. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer - updates of radiobiology, techniques, and clinical outcomes. Discov. Med. 9(48), 411-417 (2010).
3. Grills IS1, Mangona VS, Welsh R et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J. Clin. Oncol. 28(6), 928-935 (2010).
4. Padda SK, Burt BM, Trakul N, Wakelee HA. Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin. Oncol. 41(1), 40-56 (2014).
5. Martini N, Bains MS, Burt ME et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 109(1), 120-129 (1995).
6. Rena O, Oliaro A, Cavallo A et al. Stage I non-small cell lung carcinoma: really an early stage? Eur. J. Cardiothorac Surg. 21(3), 514-519 (2002).
7. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-60 (2004).
8. Butts CA, Ding K, Seymour L et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
9. Butts CA, Ding K, Seymour L et al. Randomized Phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol. 28(1), 29-34 (2010).
10. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7(9), 719-727 (2006).
11. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
12. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722), 1267-1277 (2010).
13. Strauss GM, Herndon JE, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 26(31), 5043-5051 (2008).
14. Arriagada R, Dunant A, Pignon JP et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol. 28(1), 35-42 (2010).
15. Besse B, Le Chevalier T. Developments in the treatment of early NSCLC: when to use chemotherapy. Ann. Oncol. 23(Suppl. 10), x52-x59 (2012).
16. Song WA, Zhou NK, Wang W et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J. Thorac. Oncol. 5(4), 510-516 (2010).
17. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383(9928), 1561-1571 (2014).
18. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst. Rev. 2, CD002142 (2005).
19. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 16(5), 672-681 (2011).
20. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
21. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 382(9893), 709-719 (2013).
22. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117-1134 (2010).
23. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005).
24. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21(20), 3798-3807 (2003).
25. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12(18), 5268-5272 (2006).
26. Mendelsohn J1, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19(56), 6550-6565 (2000).
27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
28. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
29. Santarpia M, Altavilla G, Salazar MF et al. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Rev. Respir. Med. 5(3), 413-424 (2011).
30. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
31. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
32. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
33. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
34. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
35. Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Targets Ther. 6, 135-143 (2013).
36. Sequist LV1, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin Oncol. 31(27), 3327-3334 (2013).
37. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol. 15(2), 213-222 (2014).
38. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
39. Douillard JY, Pirker R, O'Byrne KJ et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. 9(5), 717-724 (2014).
40. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26(15), 2450-2456 (2008).
41. Raben D, Helfrich B, Chan D et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin. Oncol. 29, 37-46 (2002).
42. Chinnaiyan P, Huang S, Vallabhaneni G et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65(8), 3328-3335 (2005).
43. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 17(5), 682-693 (2012).
44. Wan J, Cohen V, Agulnik J et al. Unexpected high lung toxicity from radiation pneumonitis in a Phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 75, S110 (2009).
45. Okamoto I, Takahashi T, Okamoto H et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72, 199-204 (2001).
46. Nanda A, Dias-Santagata DC, Stubbs H et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin. Lung Cancer 9(5), 285-287 (2008).
47. Goss GD, O'Callaghan C, Lorimer I et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J. Clin. Oncol. 31(27), 3320-3326 (2013).
48. Janjigian YY, Park BJ, Zakowski MF et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J. Thorac. Oncol. 6(3), 569-575 (2011).
49. D'Angelo SP, Janjigian YY, Ahye N et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J. Thorac. Oncol. 7(12), 1815-1822 (2012).
50. Li N, Ou W, Ye X et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, Phase II study. Ann. Surg. Oncol. 21(6), 2091-2096 (2014).
51. Shepherd F, Altorki NK, Eberhardt WE et al. Adjuvant erlotinib versus placebo in non-small cell lung cancer patients with tumors carrying EGFR-sensitizing mutations form the RADIANT trial. J. Clin. Oncol. 32(5s), Abstract 7513 (2014).
52. Wislez M, Barlesi F, Besse B et al. Customized adjuvant Phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J. Clin. Oncol. 32(12), 1256-1261 (2014).
53. Kelly K, Altorki NK, Eberhardt WE et al. A randomized, double-blind Phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J. Clin. Oncol. 32(5s), Abstract 7501(2014).
54. Pennell NA, Neal JW, Chaft J et al. SELECT: a multicenter Phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. J. Clin. Oncol. 32(5s), Abstract 7514 (2014).
55. Tada H, Takeda K, Nakagawa K et al. Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer harboring activating EGFR mutation (WJOG6410L). J. Clin. Oncol. 30(Suppl. 15), Abstract TPS7110 (2012).
56. O'Brien ME, Eberhardt WE, Altorki NK et al. Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial. J. Clin. Oncol. 32(Suppl. 5), Abstract 7535 (2014).
57. Neal JW, Pennell NA, Govindan R et al. The SELECT study: a multicenter Phase II trial of adjuvant erlotinib in resected epidermal growth factor recpetor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl. 15), Abstract 7010 (2010).
58. Govindan R1, Bogart J, Stinchcombe T et al. Randomized Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J. Clin. Oncol. 29(23), 3120-3125 (2011).
59. Blumenschein GR Jr, Paulus R et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J. Clin. Oncol. 29(17), 2312-2318 (2011).
60. Bradley J, Paulus R, Komaki R et al. A randomized Phase III comparison of standard dose (60 Gy) versus High-Dose (74 Gy) conformal radiotherapy with or without cetuximab in patients with cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J. Clin. Oncol. 31(Suppl.), Abstract 7501 (2013).
61. Bradley J, Masters G, Hu C et al. An intergroup randomized Phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy +/- cetuximab for stage III non-small cell lung cancer: results from RTOG 0617. J. Thorac. Oncol. S3, Abstract PL03.05 (2013).
62. Govindan R. Lung cancer: molecular profiling and genomics. Extended education session. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 31 May 2013.
63. ClinicalTrials.gov. Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation. https://clinicaltrials.gov
64. ClinicalTrials.gov. Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation. https://clinicaltrials.gov
65. Joensuu H1, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12), 1265-1272 (2012).
66. Fan W, Tang Z, Yin L et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71(13), 4494-4505 (2011).
67. Li R, Hu Z, Sun SY et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 12(10), 2200-2212 (2013).
68. Lu Y1, Govindan R, Wang L et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33(5), 1046-1054 (2012).
69. Tufman A, Tian F, Huber RM. Can microRNAs improve the management of lung cancer patients? A clinician's perspective. Theranostics 3(12), 953-963 (2013).
70. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
71. Izumchenko E, Chang X, Michailidi C et al. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 74(14), 3995-4004 (2014).
72. Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol. Med. 10(4), 192-205 (2013).
73. Schaake EE, Kappers I, Codrington HE et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 30(22), 2731-2738 (2012).
74. Lara-Guerra H, Waddell TK, Salvarrey MA et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6229-6236 (2009).
75. Rizvi NA, Rusch V, Pao W et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin. Cancer Res. 17(10), 3500-3506 (2011).